540 postmenopausal women with normal to low bone mineral density were randomized to 24 months of treatment with either lasofoxifene 0.25mg/day, raloxifene 60mg/day, or daily placebo. The purpose of this study was to compare changes in bone mineral density and bone turnover markers between groups after 24 months of treatment. Change in bone mineral density of the lumbar spine and total hip were reported to significantly favour the lasofoxifene group compared to both the raloxifene group and placebo group. Both lasofoxifene and raloxifene were reported to result in a significantly greater reduction in bone turnover markers compared to the placebo group.